Track) is (a) a useful way of focusing the SBIR program on companies with strong commercialization capabilities; (b) good public policy?) What factors influence a firm’s decision to participate in Fast Track?
What factors inhibit a firm’s participation in Fast Track?
What benefits do firms expect to gain from a Fast Track award not available through the regular Phase II process?
Does the Fast Track award affect the performance of firms? How (e.g., in terms of research capabilities or commercialization prospects)?
What specific effects does the presence of a third-party investor have on performance?
Are differential impacts of Fast Track observed by region, DoD funding agency, or firm characteristics?
What do participating firms see as strengths and weaknesses of the Fast Track program?